Obalon Therapeutics, Inc. (OBLN) Management on Q3 2019 Results - Earnings Call Transcript

Obalon Therapeutics, Inc. (OBLN) Q3 2019 Earnings Conference Call November 8, 2019 9:00 AM ET

Company Participants

Bill Plovanic - Chief Executive Officer
Bob Macdonald - Chief Retail Officer
Nooshin Hussainy - Chief Financial Officer

Conference Call Participants

Ben Haynor - Alliance Global
Kyle Rose - Canaccord

Operator

Good day, ladies and gentlemen, and welcome to the Obalon Therapeutics Third Quarter 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Bill Plovanic, Chief Executive Officer for Obalon. Mr. Plovanic you may begin.

Bill Plovanic

Thank you, operator. Good morning, and welcome to Obalon Therapeutics third quarter financial results conference call. With me on today's call are Bob Macdonald, Chief Retail Officer; and Nooshin Hussainy, Chief Financial Officer.

This morning, the company issued a press release detailing our financial results for the three months ended September 30, 2019. This release can be accessed through the Investor Relations section of the Obalon website at obalon.com. You can also access the webcast of this call from there.

Before we get started, I'd like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. Forward-looking statements in this release include Obalon's expectations regarding the near and the long-term growth potential of its business including the company-owned retail treatment centers.

These forward-looking statements are based on information available to Obalon management as of today and involve risks and uncertainties, which include, but are